Five Prime: Phase 2 Cabiralizumab/Opdivo Study Misses Endpoint

By Colin Kellaher

Five Prime Therapeutics Inc. on Tuesday said it was informed by Bristol-Myers Squibb Co. that a Phase 2 study testing the combination of Five Prime's cabiralizumab with Bristol's Opdivo in patients with advanced pancreatic cancer didn't meet its primary endpoint.

Five Prime, a South San Francisco, Calif., clinical-stage biotechnology company, said Bristol has no near-term plans for additional sponsored development of cabiralizumab.

However, Five Prime said the New York drug maker will continue to support the evaluation of cabiralizumab in select, ongoing investigator-sponsored trials and may continue to assess future development opportunities for the investigational antibody.

Five Prime noted that Bristol, which acquired rights to cabiralizumab in October 2015 under an exclusive worldwide license and collaboration agreement, also reported that no new safety signals were observed in the study.

Shares of Five Prime slipped 4.2% to $4.34 in early trading Tuesday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 18, 2020 10:20 ET (15:20 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024